- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT01665599
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel
A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Ontario
-
London, Ontario, Kanada
- St. Joseph's Healthcare
-
North Bay, Ontario, Kanada
- Private Practice and Clinical Research
-
-
-
-
Alabama
-
Huntsville, Alabama, Vereinigte Staaten
- Medical Affiliated Research Cente
-
-
California
-
Newport Beach, California, Vereinigte Staaten
- California Professional Research
-
San Diego, California, Vereinigte Staaten
- San Diego Sexual Medicine
-
-
Connecticut
-
Middlebury, Connecticut, Vereinigte Staaten
- Connecticut Clinical Research
-
-
Florida
-
Aventura, Florida, Vereinigte Staaten
- South Florida Medical Research
-
-
Michigan
-
Saint Clair Shores, Michigan, Vereinigte Staaten
- Michigan Institute of Urology
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten
- Quality Clinical Research
-
-
New Jersey
-
Lawrenceville, New Jersey, Vereinigte Staaten
- Premier Urology Associates
-
-
New York
-
New York, New York, Vereinigte Staaten
- University Urology
-
Poughkeepsie, New York, Vereinigte Staaten
- Premier Medical Group of the Hudson Valley
-
-
North Carolina
-
Winston-Salem, North Carolina, Vereinigte Staaten
- PMG Research of Wilmington
-
-
Ohio
-
Cincinnati, Ohio, Vereinigte Staaten
- Tristate Urologic Services
-
-
Rhode Island
-
Warwick, Rhode Island, Vereinigte Staaten
- Omega Medical Research
-
-
South Carolina
-
Mount Pleasant, South Carolina, Vereinigte Staaten
- Coastal Carolina Research Center
-
Myrtle Beach, South Carolina, Vereinigte Staaten
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Vereinigte Staaten
- Clinical Research Associates
-
-
Texas
-
Dallas, Texas, Vereinigte Staaten
- Urology Clinics of North Texas
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Males between 18-75 years of age
- Two screening serum testosterone values less than 300 ng/dL
- One or more symptoms of testosterone deficiency
Exclusion Criteria:
- Previous use of the investigational product
- Use of any investigational product within 30 days prior to screening and during the study
- BMI less than 18 kg/m^2 or more than 35 kg/m^2
- Prostatic mass(es)
- Generalized skin irritation or skin disease
- Lower urinary tract obstruction
- Myocardial infarction or cerebrovascular accident in the last 6 months
- Unstable angina or congestive heart failure
- Thromboembolic disorders
- Sleep apnea
- Hyperparathyroidism or uncontrolled diabetes
- Untreated moderate to severe depression
- History of testicular, prostate, or breast cancer
- HIV, Hepatitis B, or Hepatitis C positive
- PSA more or equal to 3 ng/mL
- Use of any medications that could be considered anabolic
- Use of estrogens, Gonadotropin Releasing Hormone agonists/antagonists, antiandrogens, or human Growth Hormone
- Chronic use of any drug of abuse
- Involvement in a sport in which there is a screening for anabolic steroids
- Not willing to use adequate contraception during the study
- Partner is pregnant and/or breast feeding
- Partner has a history of breast, uterine or ovarian cancer
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Testosterone gel (FE 999303)
Subjects received a starting dose of 46 mg (two actuations) of testosterone gel (2%) daily in the morning. The dose was further titrated (increased or decreased - three actuations [69 mg] or single actuation [23 mg], respectively) based on serum testosterone concentrations. Testosterone gel was applied using an applicator, to the shoulder/upper arm in a contralateral fashion. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The Percentage of Subjects on Day 90 Whose Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL
Zeitfenster: Day 90
|
The data were presented using descriptive statistics.
No statistical analysis was performed.
|
Day 90
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
The Percentage of Participants on Day 1 Whose Serum Cavg (0-24) Serum Total Testosterone Levels Are Between 300 and 1050 ng/dL
Zeitfenster: Day 1
|
The data were presented using descriptive statistics.
No statistical analysis was performed.
|
Day 1
|
Pharmacokinetics of Total Testosterone Measuring Area Under the Concentration-time Curve From the Last Dose and 24 Hours Post-dose (AUCτ)
Zeitfenster: Day 1; Day 90
|
A validated high pressure liquid chromatography with tandem mass spectrometry detection (LC/MS/MS) method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of Total Testosterone Measuring Time of Maximum Observed Concentration (Tmax)
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of Total Testosterone Measuring Maximum Concentration Observed (Cmax)
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of Total Testosterone Measuring Average Steady State Concentration (Cave)
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of Total Testosterone Measuring Minimum Concentration Observed (Cmin)
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of Total Testosterone Measuring Time of Minimum Observed Concentration (Tmin)
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of total testosterone.
|
Day 1; Day 90
|
Pharmacokinetics of DHT (Dihydrotestosterone) Measuring AUCτ
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Pharmacokinetics of DHT Measuring Tmax
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Pharmacokinetics of DHT Measuring Cmax
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Pharmacokinetics of DHT Measuring Cave
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Pharmacokinetics of DHT Measuring Cmin
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Pharmacokinetics of DHT Measuring Tmin
Zeitfenster: Day 1; Day 90
|
A validated LC/MS/MS method was used to determine the levels of DHT.
|
Day 1; Day 90
|
Change From Baseline in the International Index of Erectile Dysfunction (IIEF) Questionnaire
Zeitfenster: Day 91
|
Data collected from the five domains of sexual functions were summarized by descriptive statistics. The domains are:
A score of 0-5 is awarded to questions 1 to 10 and a score of 1-5 is awarded to questions 11 to 15. Total score was calculated by summing up scores of each domain and ranged from 5 to 75. Low score indicates severe dysfunction and a high score indicates no dysfunction in sexual function. |
Day 91
|
Change From Baseline in the Multidimensional Assessment of Fatigue (MAF) Questionnaire
Zeitfenster: Day 91
|
The MAF contains four sub-domains:
A score of 1-10 is awarded to each of the 14 questions across the 3 domains. The timing domain is categorical and was converted to 1-10 scale by multiplying each score by 2.5. Lower score in each domain indicates improvement in fatigue. To calculate GFI : Score of question 15 is converted to a 0-10 scale by multiplying each score by 2.5 and then sum questions 1, 2, 3, average of 4-14, and newly scored question 15. A score of zero is assigned to question 2-16, if patient select 'no fatigue' to question 1. Question 16 is not included in GFI calculation. Range of GFI: 1 (no fatigue) to 50 (severe fatigue). The data were presented using descriptive statistics. |
Day 91
|
Change From Baseline in the SF-12 Health Questionnaire
Zeitfenster: Day 91
|
Data collected from the SF-12 questionnaire was used to assess improvement in the psychometrically-based physical component summary (PCS) and mental component summary (MCS). Both PCS and MCS contains four sub-domains: PCS: General Health (1 item), Physical Functioning (2 items), Role-Physical (2 items), Bodily Pain (1 item) MCS: Role-Emotional (2 items), Mental Health (2 items), Vitality (1 item), Social Functioning (1 item) The scale scores are calculated by summing responses across scale items and then transforming these raw scores to a 0-100 scale. Computerized scoring algorithms are used to produce norm-based scores for each scale (mean of 50 and standard deviation of 10) as well as the PCS and MCS summary scores. A zero score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. The data were presented using descriptive statistics. |
Day 91
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 000023
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Erwachsener männlicher Hypogonadismus
-
Abramson Cancer Center at Penn MedicineAktiv, nicht rekrutierendAdolescent and Young Adult (AYA) KrebsüberlebendeVereinigte Staaten
-
Icahn School of Medicine at Mount SinaiNational Institute on Deafness and Other Communication Disorders (NIDCD)AbgeschlossenMal-de-Debarquement-Syndrom (MdDS)Vereinigte Staaten
-
Icahn School of Medicine at Mount SinaiNew York University; National Institute on Deafness and Other Communication... und andere MitarbeiterRekrutierungMal-de-Débarquement-SyndromVereinigte Staaten
-
Laboratorios Casen-Fleet S.L.U.Apices Soluciones S.L.; Trial Form Support S.L.AbgeschlossenPatienten, die sich zum ersten Mal einer vollständigen explorativen diagnostischen Koloskopie unterziehen.Spanien
-
University of MinnesotaAbgeschlossenMal-de-Debarquement-SyndromVereinigte Staaten
-
University of MinnesotaZurückgezogenMal-de-Debarquement-Syndrom
-
University of MinnesotaZurückgezogenMal-de-Debarquement-SyndromVereinigte Staaten
-
University Hospital, Clermont-FerrandAbgeschlossenPatienten mit systemischen entzündlichen Erkrankungen, die zum ersten Mal eine langwierige allgemeine Kortikoidtherapie erhaltenFrankreich
-
Mostafa BahaaSahar El-Haggar, Prof Clinical pharmacy Department- Tanta University; Principal... und andere MitarbeiterRekrutierung
-
St. Boniface HospitalHeart and Stroke Foundation of CanadaRekrutierungErnährung schlecht | Kardiovaskuläre Morbidität | Gebrechliches Syndrom älterer ErwachsenerKanada
Klinische Studien zur Testosteron-Gel (FE 999303)
-
Ferring PharmaceuticalsAbgeschlossenErwachsener männlicher HypogonadismusVereinigte Staaten
-
Ferring PharmaceuticalsAbgeschlossenHypogonadale MännchenVereinigte Staaten
-
Ferring PharmaceuticalsAbgeschlossenErwachsener männlicher HypogonadismusVereinigte Staaten, Kanada
-
University of WashingtonNational Institutes of Health (NIH); National Institute on Aging (NIA)AbgeschlossenGesundVereinigte Staaten
-
University of PennsylvaniaEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossen
-
Amneal Pharmaceuticals, LLCPhase One Solutions, Inc.AbgeschlossenHypogonadotroper Hypogonadismus | Primärer HypogonadismusVereinigte Staaten
-
VA Office of Research and DevelopmentRekrutierung
-
University of WashingtonEunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenEmpfängnisverhütung | HypogonadismusVereinigte Staaten
-
Clarus Therapeutics, Inc.Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; PharmaNe...AbgeschlossenMännlicher HypogonadismusVereinigte Staaten, Deutschland
-
Seattle Institute for Biomedical and Clinical ResearchRekrutierungKrebs | Ermüdung | Hypogonadismus, männlichVereinigte Staaten